Drug prices: hepatitis b patients with hepatitis b _ drugs for at least a year, 12,000 | news
Original title: governance solutions | drug prices in patients with hepatitis b drugs for at least a year, 12,000
Beijing News Alerts (by xinna Dandan Li) today, the first batch of State drug price negotiation results announced to the public, in which the first-line treatment for chronic hepatitis b drug tenofovir disoproxil, Ecker for the targeted therapy for non-small cell lung cancer drugs and gefitinib 3 negotiating drug prices over 50%, respectively, and 67%, and 55%.
Pulmonary Oncology, said Zhou Qing, Director of Guangdong provincial people's Hospital, China new lung cancer patients each year, accounting for 20% of all tumor diseases, about 700,000 people. Non-small cell lung cancer accounts for about 80%, sensitive mutations of EGFR in patients with non-small cell lung cancer accounts for which 35%-50%, where about 200,000 people.
Previously, according to media reports, the Beijing tumor Prevention Office Deputy Director Wang Ning said 10 years the incidence of lung cancer in Beijing has grown by approximately 43%. According to the Beijing tumor Prevention Office 2012 8220 cases new cases of lung cancer were reported in Beijing, 20.39% per cent of new cases of malignant tumor, which male 5043, 77.94 incidence/100,000; 3177 females, 49.59 incidence/100,000; men 159:100.
Issued by the Beijing Municipal Government, Beijing municipal health and minority health report also showed that in 2014, leading causes of death for chronic diseases of Beijing's residents, the top three causes of death for cancer, heart disease and cerebrovascular disease, respectively, and lung, liver, colorectal and anal cancers as malignant tumor death in the top three.
Drug prices dropped, with how much to save? Zhou Qing introduced if annual figure, a sensitive mutations of EGFR in patients with non-small cell lung cancer, about to spend 150,000 yuan for the purchase of gefitinib, an anti-cancer drug, 200,000 patients would cost 30 billion yuan. Price 50% this means, just new people the drug cost savings per year, more than 15 billion yuan. And this is only the most conservative estimates.
In addition, prices also include first-line treatment for chronic hepatitis b drug in the drug tenofovir ester. In this regard, the liver Center Director Xie Wen, Beijing Ditan Hospital said about 30 million patients with chronic hepatitis b in the country, if one half of the patients can be treated more negotiations before the drug cost savings will reach 180 billion.
A hepatitis b patient told the Beijing News reporter, he was three years ago, started taking tenofovir disoproxil, still need to buy imported medicines, a bottle of some 4000 Yuan. In the domestic market of the drug after a bottle is 1470 Yuan.
At present, the patients just take tenofovir disoproxil, a bottle a month, spending 1470 Yuan. Price 490 calculation in accordance with negotiations, he can reduce drug costs about 12,000 yuan a year.
Responsible editor: Xiang Changming SN123
Article keywords:Hepatitis b
I want feedback
Save a Web page
The Beijing News
药品降价：乙肝患者药费一年至少省1.2万|乙肝_新闻资讯
原标题：政解|药品降价 乙肝患者药费一年至少省1.2万
新京报快讯（记者信娜 李丹丹）今日，首批国家药品价格谈判结果向社会公布，其中，慢性乙肝一线治疗药物替诺福韦酯，非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼3种谈判药品降价幅度均在50%以上，分别为67%、54%、55%。
广东省人民医院肺部肿瘤科主任周清表示，中国每年新发肺癌患者，约占所有肿瘤类疾病的20%，在70万人左右。其中非小细胞肺癌就占到约八成，EGFR敏感突变的非小细胞肺癌患者则占到其中35%-50%，也就是在20万人左右。
此前据媒体报道，北京市肿瘤防治办公室副主任王宁透露，10年间北京市肺癌的发病率约增长了43%。根据北京市肿瘤防治办公室统计，2012年北京市共报告肺癌新发病例8220例，占恶性肿瘤新发病例的20.39%，其中男性5043例，发病率为77.94/10万；女性3177例，发病率为49.59/10万；男女比例159：100。
北京市政府发布的《北京市卫生与人群健康状况报告》也显示，2014年北京市户籍居民的主要死亡原因为慢性病，前三位死因分别为恶性肿瘤、心脏病和脑血管病，而肺癌、肝癌、结肠直肠和肛门癌列为恶性肿瘤死亡的前三位。
药品价格下降后，患者到底能省多少钱？周清介绍，如果按年算，一个EGFR敏感突变的非小细胞肺癌患者，大约要花15万元用于购买吉非替尼抗癌药，20万名病人就将花费300亿元。降价幅度50%则意味着，每年仅仅是新发病人省下的药物费用，就超过150亿元。而这还只是最保守的测算。
此外，降价药品中还包括慢性乙肝一线治疗药物替诺福韦酯。对此，北京地坛医院肝病中心主任谢雯表示，全国约3000万慢性乙肝患者中，如果其中一半的患者可以接受治疗，较谈判之前省下的药物费用将达到1800亿。
一位乙肝患者告诉新京报记者，他是三年前开始服用替诺福韦酯，当时仍需购买进口药，一瓶约4000元。后该药在国内上市，一瓶为1470元。
目前，该名患者基本只需吃替诺福韦酯，一个月一瓶，花费1470元。按照谈判后价格490元计算，他每年可减少药品花费约1.2万元。
责任编辑：向昌明 SN123
文章关键词： 乙肝
新京报